{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:50:33Z","timestamp":1740142233984,"version":"3.37.3"},"reference-count":48,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,2,28]]},"DOI":"10.2217\/fon-2018-0512","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T11:26:47Z","timestamp":1542626807000},"page":"663-681","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["A Comparative Evaluation of Gemtuzumab Ozogamicin\u00a0+\u00a0Daunorubicin-Cytarabine and Other Treatments for Newly Diagnosed Acute Myeloid Leukemia"],"prefix":"10.1080","volume":"15","author":[{"given":"Ajibade O","family":"Ashaye","sequence":"first","affiliation":[{"name":"Evidera Inc., Waltham, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarmina","family":"Khankhel","sequence":"additional","affiliation":[{"name":"Evidera Inc., Waltham, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxin","family":"Xu","sequence":"additional","affiliation":[{"name":"Evidera Inc., Waltham, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Fahrbach","sequence":"additional","affiliation":[{"name":"Evidera Inc., Waltham, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Mokgokong","sequence":"additional","affiliation":[{"name":"Pfizer Ltd, Surrey, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle E","family":"Orme","sequence":"additional","affiliation":[{"name":"ICERA Consulting Ltd, Swindon, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Lang","sequence":"additional","affiliation":[{"name":"Pfizer Ltd, Surrey, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Mamolo","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,11,19]]},"reference":[{"key":"e_1_3_3_3_1","unstructured":"American Cancer Society . Key statistics for acute myeloid leukemia (2018). www.cancer.org\/cancer\/acute-myeloid-leukemia\/about\/key-statistics.html."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620714532123"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"issue":"4","key":"e_1_3_3_6_1","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates JW","year":"1973","unstructured":"Yates JW , WallaceHJJr, EllisonRR, HollandJF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother. Rep.57(4), 485\u2013488 (1973).","journal-title":"Cancer Chemother. Rep."},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2012.10.005"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.10.2520.2520"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971201)80:11 <2210::AID-CNCR8>3.0.CO;2-L"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.6.6"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.38"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.4.1048.1048"},{"key":"e_1_3_3_13_1","volume-title":"Drug Approval Package","author":"US FDA","year":"2000","unstructured":"US FDA . NDA 21\u2013174: Mylotarg (gemtuzumab ozogamicin) Injection. Drug Approval Package. Company: Wyeth-Ayerst. Approval Date: 5\/17\/2000. New Drug Application No.: 21\u2013174 (2000). www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/21174_Mylotorg.cfm."},{"key":"e_1_3_3_14_1","unstructured":"US FDA . Proposed text of labeling for the drug - annotated: Mylotarg\u2122 (gemtuzumab ozogamicin for Injection) (2000). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2000\/21174lbl.pdf."},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70281-5"},{"key":"e_1_3_3_16_1","unstructured":"US FDA . FDA approves Mylotarg for treatment of acute myeloid leukemia (2017). www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm574507.htm."},{"key":"e_1_3_3_17_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT","year":"2011","unstructured":"Higgins JPT , GreenS (Eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0[updated March 2011]. The Cochrane Collaboration (2011). www.handbook.cochrane.org."},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.897"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458724"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13487604"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1875"},{"key":"e_1_3_3_24_1","author":"National Institute for Health and Care Excellence (NICE)","year":"2013","unstructured":"National Institute for Health and Care Excellence (NICE) . Guide to the Methods of Technology Appraisal 2013 (2013). www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.","journal-title":"Guide to the Methods of Technology Appraisal 2013"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-139"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3680"},{"issue":"4","key":"e_1_3_3_29_1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks SPG","year":"1998","unstructured":"Brooks SPG . General methods for monitoring convergence of iterative simulations. J. Comput. Graph. Stat.7(4), 434\u2013455 (1998).","journal-title":"J. Comput. Graph. Stat."},{"key":"e_1_3_3_30_1","first-page":"131","volume-title":"Markov Chain Monte Carlo in Practice","author":"Gelman A","year":"1996","unstructured":"Gelman A . Inference and monitoring convergence. In: Markov Chain Monte Carlo in Practice. GilksWR, RichardsonS, SpiegelhalterDJ (Eds). Chapman and Hall, London, 131\u2013143 (1996)."},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9868.00353"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.00423.x"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273243"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1686"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.2652"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2907"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12528"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30883"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0354"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07604.x"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.4310"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2964"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3561"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1302"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403336"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.1286"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04702.x"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.6490"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-420596"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2018-0512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:54Z","timestamp":1719125094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2018-0512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,19]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,2,28]]}},"alternative-id":["10.2217\/fon-2018-0512"],"URL":"https:\/\/doi.org\/10.2217\/fon-2018-0512","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2018,11,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}